Tyra biosciences announces first child dosed in beach301, its phase 2 study for dabogratinib (tyra-300) in pediatric achondroplasia

-dabogratinib is the only oral fgfr3-selective inhibitor in clinical development for achondroplasia- -initial results from safety sentinel cohort expected in 2h 2026- carlsbad, calif. , aug. 21, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that the first child has been dosed in beach301, a phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism.
TYRA Ratings Summary
TYRA Quant Ranking